SCHEDULE 13G/A: BlackRock Amends Akebia Therapeutics Stake, Reports 6.1% Passive Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.1% passive ownership stake in Akebia Therapeutics Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 1 to its Schedule 13G regarding its beneficial ownership in Akebia Therapeutics Inc.
- As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 15,141,768 shares of Akebia Therapeutics Inc. Common Stock.
- This ownership represents 6.1% of Akebia Therapeutics Inc.'s outstanding Common Stock.
- BlackRock holds sole voting power over 14,870,256 shares and sole dispositive power over 15,141,768 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Akebia Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G amendment) disclosing passive ownership. It does not contain information that would inherently suggest a positive or negative sentiment towards the issuer's operational performance or future prospects. The sentiment is neutral as it simply reports a factual ownership stake.
Positives
- BlackRock, a major institutional investor, maintains a significant passive stake of 6.1% in Akebia Therapeutics Inc., indicating continued confidence in the company as an investment.
- The filing confirms that BlackRock's investment is for ordinary course of business purposes, not for control, which can provide stability regarding the company's governance.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Akebia Therapeutics Inc.'s business or financial performance.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." Spencer Fleming, Managing Director, BlackRock, Inc.
Industry Context
This filing is a routine disclosure of institutional ownership, common among large asset managers like BlackRock. It reflects BlackRock's ongoing investment activities and portfolio management across various public companies, including those in the biotechnology or pharmaceutical sector like Akebia Therapeutics.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
- Management: Confirms that a major institutional investor holds a passive stake, reducing immediate concerns about activist intervention.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. signatories. |
| 2025-03-31 | Date of event which required the filing of this Schedule 13G amendment. |
| 2025-04-17 | Date of filing of the Schedule 13G amendment by BlackRock, Inc. |
Keywords
Akebia Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.